William Blair analyst Myles Minter has reiterated their bullish stance on ARCT stock, giving a Buy rating on April 11.
Myles Minter’s rating is based on the promising potential of Arcturus Therapeutics’ proprietary technologies, STARR and LUNAR, which have recently received regulatory approvals in Japan and the EU. Despite some challenges in the vaccine segment, investor interest is shifting towards the anticipated Phase II data for ARCT-032 in cystic fibrosis, expected in the second quarter of 2025.
Minter highlights the encouraging results from a prior Phase Ib study, where ARCT-032 demonstrated a 4% increase in FEV1 in cystic fibrosis patients already on Trikafta treatment. The upcoming Phase II study will focus on patients not receiving background therapy, with a target of a 3% increase in FEV1 to advance to further trials. This target aligns with the standards set by Vertex for its CFTR mRNA treatment, indicating a competitive edge for Arcturus in the cystic fibrosis treatment landscape.
In another report released on April 11, H.C. Wainwright also maintained a Buy rating on the stock with a $60.00 price target.